Table 2. Univariate analysis of baseline characteristics for RFS.

	Non-recurrence n=11	Recurrence n=14	HR	95%CI	p value
Age (≥65/65>)	6/5	10/4	1.619	0.507-5.172	0.416
Gender (M/F)	8/3	12/2	0.633	0.141-2.833	0.550
Tumor size (≥50/50> mm)	2/9	4/10	1.478	0.462-4.732	0.510
ALT (≥40/40> IU/l)	5/6	12/2	4.248	0.947-19.063	0.059
HBV infection (+/-)	0/11	2/12	3.685	0.759-17.900	0.106
HCV infection (+/-)	7/4	11/3	1.677	0.467-6.030	0.428
Hepatic fibrosis (non-LC/LC)	10/1	4/10	5.706	1.700-19.153	0.005
pre-AFP (≥10/10> ng/ml)	4/7	9/5	1.998	0.666-5.992	0.217
post-AFP (≥10/10> ng/ml)	3/8	5/9	1.006	0.337-3.008	0.991
pre-PIVAKA- II (≥40/40> mAU/ml)	7/4	10/4	1.494	0.466-4.792	0.499
post-PIVAKA- II (≥40/40> mAU/ml)	1/10	1/13	0.659	0.086-5.056	0.688
pre-GPC3 (≥132/132> ng/ml)	2/9	8/6	2.152	0.745-6.126	0.157
post-GPC3 (≥132/132> ng/ml)	0/11	7/7	3.575	1.239-10.314	0.018
IHC GPC3 (+/-)*	4/5**	9/5	1.927	0.643-5.773	0.241

* Immunohistochemical staining of GPC3

**two cases were not available